InvestSMART

Percheron Therapeutics Limited (ASX:PER)

ALERT: Price-sensitive ASX Announcement for PER
Current share price for PER : $0.004 -0.007 (-63.64%)+
Announcement
Release
28 Aug 2025 1:33PM
Price at Release
$0.011
Full Release
download
Summary
The document is the Appendix 4E and Annual Report for Percheron Therapeutics Limited for the year ended 30 June 2023. It provides a comprehensive overview of the company's performance, financial position, and key activities during the year. The report details the principal activities of the company, financial results, review of operations, changes in the business, operating and financial review, significant accounting policies, risk management, and future developments. It also includes directors’ and auditor’s reports, statement of profit or loss and other comprehensive income, statement of financial position, statement of changes in equity, statement of cash flows, and notes to the financial statements. The company reports a loss for the year, continues to focus on drug development, and discusses its research progress, funding strategies, corporate governance, and compliance with ASX listing rules.
Key Points
  • Percheron Therapeutics Limited released its Appendix 4E and Annual Report for the year ended 30 June 2023.
  • The company’s principal activities involve drug development with a focus on advancing its research pipeline.
  • A net loss was reported for the financial year, reflecting ongoing investment in research and development.
  • The report outlines significant changes in the company's operations and financial position over the past year.
  • Directors’ and auditor’s reports are included, highlighting corporate governance and audit findings.
  • Detailed financial statements provide insights into revenues, expenditures, assets, liabilities, and equity.
  • Risk management strategies and future outlook are discussed, emphasizing continued focus on clinical milestones and financing opportunities.
  • The company remains committed to compliance with ASX listing rules and continuous disclosure obligations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.